Mineralys Therapeutics
MLYS
13.66
-0.50
-3.53%
Mineralys Therapeutics
US · MLYS
#2760 by market cap
Listed 2023
13.66
-0.50
-3.53%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)TipRanks · 2026/8/13
-
Rating change
Guggenheim Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $48Market Newswire · 2026/5/19
-
Rating change
BofA Securities Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $49Market Newswire · 2026/10/12
-
UBS Maintains Mineralys Therapeutics(MLYS.US) With Hold Rating, Maintains Target Price $29Market Newswire · 2026/10/12
-
Rating change
Bank of America Securities Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)TipRanks · 2026/8/12
-
Rating change
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $40 to $56Market Newswire · 2026/8/13
-
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $17 to $56Market Newswire · 2026/11/6
-
Rating change
UBS Initiates a Hold Rating on Mineralys Therapeutics, Inc. (MLYS)TipRanks · 2026/10/12
-
Rating change
LifeSci Capital Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $54Market Newswire · 2026/8/12
-
Rating change
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Palvella Therapeutics (PVLA) and Mineralys Therapeutics, Inc. (MLYS)TipRanks · 2026/10/12
-
Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/11/6
-
Rating change
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $42 to $56Market Newswire · 2026/5/8
-
H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $56Market Newswire · 2026/11/10
-
Rating change
Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Mineralys Therapeutics, Inc. (MLYS)TipRanks · 2026/10/12
-
UBS Maintains Mineralys Therapeutics(MLYS.US) With Hold Rating, Cuts Target Price to $19Market Newswire · 2026/11/6
-
Rating change
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)TipRanks · 2026/6/4
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), Legend Biotech (LEGN) and Mineralys Therapeutics, Inc. (MLYS)TipRanks · 2026/8/12
-
Rating change
Goldman Sachs Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $42Market Newswire · 2026/6/4
-
Rating change
UBS Initiates Mineralys Therapeutics(MLYS.US) With Hold Rating, Announces Target Price $29Market Newswire · 2026/10/12
-
Rating change
Mineralys Therapeutics, Inc. (MLYS) Gets a Buy From Wells FargoTipRanks · 2026/8/12
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL), Myriad Genetics (MYGN) and Mineralys Therapeutics, Inc. (MLYS)TipRanks · 2026/5/8
-
Mineralys Therapeutics (MLYS.US) will release its financial report after the market close on November 4.Market Newswire · 2026/10/30
-
H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $56Market Newswire · 2026/10/23
-
Rating change
Analysts Are Bullish on Top Healthcare Stocks: CVS Health (CVS), Mineralys Therapeutics, Inc. (MLYS)TipRanks · 2026/5/7
-
Rating change
TD Cowen Maintains Mineralys Therapeutics(MLYS.US) With Buy RatingMarket Newswire · 2026/5/7
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Mineralys Therapeutics discussion 0 comments